Toremifene, a novel antiestrogen, can overcome hsp27-induced drug resistance in human breast cancer cells

David M. Mahvi; Stephen W. Carper; Conrad O. Yu; Teresa A. McCausland; F. Kristian Storm

doi:10.1007/bf02738693

Toremifene, a novel antiestrogen, can overcome hsp27-induced drug resistance in human breast cancer cells

David M. Mahvi, Stephen W. Carper^*, Conrad O. Yu, Teresa A. McCausland, F. Kristian Storm

^*Corresponding author for this work

Surgery, Surgical Oncology Division

Research output: Contribution to journal › Article › peer-review

7 Scopus citations

Abstract

Human breast cancer cell lines derived from MDA-MB-231 were constructed to express hsp27 constitutively. The elevated presence of this protein resulted in an enhanced ability to survive a heat shock and exposure to doxorubicin, a chemotherapeutic agent. Hsp217 expression was unable to protect cells from doxorubicin if they were cultured in the presence of toremifene. Flow cytometry analysis indicated that cells exposed to both toremifene and doxorubicin accumulate at G2 + M. Protective effects of hsp27 were overcome by addition of an estrogen antagonist at clinically nontoxic levels. Addition of toremifene to chemotherapeutic regimes may enhance the sensitivity of breast cancer cells to doxorubicin.

Original language	English (US)
Pages (from-to)	269-275
Number of pages	7
Journal	Endocrine
Volume	4
Issue number	3
DOIs	https://doi.org/10.1007/bf02738693
State	Published - Jun 1996

Keywords

Breast cancer
Chemotherapy
Heat shock protein
Toremifene
hsp27

ASJC Scopus subject areas

Endocrinology, Diabetes and Metabolism
Endocrinology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/bf02738693

Cite this

@article{1bfbab72a6dc46508ee3f8931d506dc7,

title = "Toremifene, a novel antiestrogen, can overcome hsp27-induced drug resistance in human breast cancer cells",

abstract = "Human breast cancer cell lines derived from MDA-MB-231 were constructed to express hsp27 constitutively. The elevated presence of this protein resulted in an enhanced ability to survive a heat shock and exposure to doxorubicin, a chemotherapeutic agent. Hsp217 expression was unable to protect cells from doxorubicin if they were cultured in the presence of toremifene. Flow cytometry analysis indicated that cells exposed to both toremifene and doxorubicin accumulate at G2 + M. Protective effects of hsp27 were overcome by addition of an estrogen antagonist at clinically nontoxic levels. Addition of toremifene to chemotherapeutic regimes may enhance the sensitivity of breast cancer cells to doxorubicin.",

keywords = "Breast cancer, Chemotherapy, Heat shock protein, Toremifene, hsp27",

author = "Mahvi, {David M.} and Carper, {Stephen W.} and Yu, {Conrad O.} and McCausland, {Teresa A.} and {Kristian Storm}, F.",

year = "1996",

month = jun,

doi = "10.1007/bf02738693",

language = "English (US)",

volume = "4",

pages = "269--275",

journal = "Endocrine",

issn = "1355-008X",

publisher = "Humana Press",

number = "3",

}

TY - JOUR

T1 - Toremifene, a novel antiestrogen, can overcome hsp27-induced drug resistance in human breast cancer cells

AU - Mahvi, David M.

AU - Carper, Stephen W.

AU - Yu, Conrad O.

AU - McCausland, Teresa A.

AU - Kristian Storm, F.

PY - 1996/6

Y1 - 1996/6

N2 - Human breast cancer cell lines derived from MDA-MB-231 were constructed to express hsp27 constitutively. The elevated presence of this protein resulted in an enhanced ability to survive a heat shock and exposure to doxorubicin, a chemotherapeutic agent. Hsp217 expression was unable to protect cells from doxorubicin if they were cultured in the presence of toremifene. Flow cytometry analysis indicated that cells exposed to both toremifene and doxorubicin accumulate at G2 + M. Protective effects of hsp27 were overcome by addition of an estrogen antagonist at clinically nontoxic levels. Addition of toremifene to chemotherapeutic regimes may enhance the sensitivity of breast cancer cells to doxorubicin.

AB - Human breast cancer cell lines derived from MDA-MB-231 were constructed to express hsp27 constitutively. The elevated presence of this protein resulted in an enhanced ability to survive a heat shock and exposure to doxorubicin, a chemotherapeutic agent. Hsp217 expression was unable to protect cells from doxorubicin if they were cultured in the presence of toremifene. Flow cytometry analysis indicated that cells exposed to both toremifene and doxorubicin accumulate at G2 + M. Protective effects of hsp27 were overcome by addition of an estrogen antagonist at clinically nontoxic levels. Addition of toremifene to chemotherapeutic regimes may enhance the sensitivity of breast cancer cells to doxorubicin.

KW - Breast cancer

KW - Chemotherapy

KW - Heat shock protein

KW - Toremifene

KW - hsp27

UR - http://www.scopus.com/inward/record.url?scp=0029779370&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029779370&partnerID=8YFLogxK

U2 - 10.1007/bf02738693

DO - 10.1007/bf02738693

M3 - Article

C2 - 21153283

AN - SCOPUS:0029779370

SN - 1355-008X

VL - 4

SP - 269

EP - 275

JO - Endocrine

JF - Endocrine

IS - 3

ER -

Toremifene, a novel antiestrogen, can overcome hsp27-induced drug resistance in human breast cancer cells

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this